Karo Pharma AB KARBF:OTCPK

RT Quote | Exchange | USD
Last | 03/30/21 EDT
5.76UNCH (UNCH)
52 week range
5.76 - 5.76
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.76
  • 52 Week High5.76
  • 52 Week High Date03/30/21
  • 52 Week Low5.76
  • 52 Week Low Date03/30/21

Key Stats

  • Market Cap1,282.83M
  • Shares Out226.3M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.76
  • 52 Week High5.76
  • 52 Week High Date03/30/21
  • 52 Week Low5.76
  • 52 Week Low Date03/30/21
  • Market Cap1,282.83M
  • Shares Out226.3M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-880.60
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date05/03/2018
  • Div Amount0.30
  • Split Date-
  • Split Factor-

Latest On Karo Pharma AB

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which...
Patrick Smallcombe
Independent Chairman of the Board
Christoffer Lorenzen
Chief Executive Officer
Jon Johnsson
Chief Financial Officer
Sofia Pedersen
Vice President - Scientific Affairs
Lisa Westerdahl
Vice President - Commercial Pharma Operations and Corporate Communications
Address
Klara Norra Kyrkogata 33
Stockholm
111 22
Sweden